Orbion Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Orbion Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Orbion Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.9M Trade | TransData Nexus

Orbion Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Antifungals Specialist · $1.9M Total Trade · DGFT Verified

Orbion Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.9M across 2 products in 2 therapeutic categories. Based on 66 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Terbinafine ($1.1M), Loperamide ($735.1K), .

Orbion Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Orbion Pharmaceuticals Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Orbion Pharmaceuticals Private Limited? — Company Overview & Market Position

Orbion Pharmaceuticals Private Limited is a privately held pharmaceutical company established on May 31, 2021, in Kanchipuram, Tamil Nadu, India. The company operates under the Corporate Identification Number (CIN) U24100TN2021FTC143806 and is registered with the Registrar of Companies, Chennai. It is a subsidiary of a foreign company, with an authorized and paid-up capital of ₹175 crore (approximately $23 million USD).

The company's manufacturing facility is located at Plot B5 (Part) & Plot B6 (Part), Sipcot Industrial Park, Irrungatukottai, Sriperumbudur Tal, Kanchipuram, Tamil Nadu, 602117, India. Orbion Pharmaceuticals specializes in the research, development, manufacturing, and marketing of generic pharmaceutical products, focusing on finished dose formulations such as tablets, capsules, syrups, and injections. The company has a global presence, exporting its products to over 40 countries, including the USA, UK, and EU regions.

What Does Orbion Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Terbinafine$1.1M 2

Product Portfolio — Top 2 by Export Value

Orbion Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Terbinafine	Antifungals	$1.1M	46	4.1%	7
2	Loperamide	Gastrointestinal	$735.1K	20	1.0%	13

Orbion Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.9M. The top category is Antifungals (60.6% of portfolio), followed by Gastrointestinal (39.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Orbion Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Orbion Pharmaceuticals operates a state-of-the-art manufacturing facility spanning 4.97 acres, designed to meet the stringent requirements of international markets. The facility is capable of producing up to 1.1 billion tablets and capsules annually, primarily serving customers in the USA and Europe. It comprises four cGMP-compliant manufacturing modules, ensuring adherence to global quality standards. Additionally, the facility includes cGMP-compliant packaging, quality control and stability laboratories, warehousing, and packing areas, all contributing to the company's commitment to quality and regulatory compliance.

3Key Leadership

The leadership team at Orbion Pharmaceuticals comprises seasoned professionals with extensive experience in the pharmaceutical industry:

Ashok Kumar Hegde, Managing Director, holds a degree in Pharmacy from Bangalore University and an M.S. in Pharmaceutical Technology from Vinayaka Mission University, Salem. He has over 20 years of experience, having successfully handled major regulatory audits and managed projects in oral solids, semi-solids, and oral liquids.

Phanindranath "Nath" Punji, Director, brings over 25 years of experience in the generic pharmaceutical industry. He previously served as Vice President of Supply Chain, Purchasing, and Projects for Ranbaxy in North America, overseeing the construction of key manufacturing facilities and the development of efficient supply chain processes.

Mridul Dhanuka, Whole Time Director, is responsible for operations and has been instrumental in realigning the supply chain from procurement to sales. He led the expansion of production facilities and the establishment of a world-class manufacturing facility at Keshwana, Rajasthan.

Bajrang Dass Garg, Independent Director, has 45 years of management experience, having risen to the position of Executive Director at Jindal Aluminum in 2011. He has been instrumental in the company's growth and development initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Orbion Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Orbion Pharmaceuticals has established a strong presence in regulated markets, particularly in the USA and the EU. The company has developed and manufactured generic products in the oral solid dosage category (excluding penicillin and cephalosporins) for these regions. As of the latest available data, Orbion has approximately 29 Abbreviated New Drug Applications (ANDAs) and 29 Drug Master Files (DMFs) approved by the US Food and Drug Administration (FDA) and European regulatory agencies. This extensive portfolio underscores Orbion's commitment to meeting the stringent regulatory requirements of these markets.

The company's manufacturing facility is an Export Oriented Unit (EOU), predominantly exporting products to the US and EU markets. It is inspected and approved by various regulatory agencies, including the US FDA and the UK Medicines and Healthcare Regulatory Agency (MHRA). This regulatory compliance ensures that Orbion's products meet the quality and safety standards required for these markets.

2Emerging Markets

Orbion Pharmaceuticals has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as evidenced by approvals from agencies such as the US FDA and UK MHRA, facilitates its entry into these regions. While specific details regarding WHO prequalification are not provided, the company's global presence and regulatory compliance suggest a strategic approach to penetrating these emerging markets.

Orbion Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Orbion Pharmaceuticals has achieved significant milestones in the US market, with approximately 29 ANDAs approved by the US FDA. This extensive portfolio indicates the company's capability to develop and manufacture generic pharmaceutical products that meet the FDA's rigorous standards. The manufacturing facility, an Export Oriented Unit (EOU), is inspected and approved by the US FDA, ensuring compliance with Good Manufacturing Practices (GMP) and other regulatory requirements.

2WHO & EU GMP

Orbion Pharmaceuticals' manufacturing facility is an Export Oriented Unit (EOU), predominantly exporting products to the US and EU markets. It is inspected and approved by various regulatory agencies, including the US FDA and the UK Medicines and Healthcare Regulatory Agency (MHRA). While specific details regarding WHO prequalification and EU GMP certificates are not provided, the company's adherence to international quality standards and regulatory approvals suggests compliance with these certifications.

3CDSCO & Indian Regulatory

Orbion Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Orbion Pharmaceuticals operates in the competitive generic pharmaceutical market, focusing on finished dose formulations such as tablets, capsules, syrups, and injections. While specific competitors are not identified in the available information, the company's extensive portfolio of approximately 29 ANDAs and 29 DMFs approved by the US FDA and European regulatory agencies positions it as a significant player in the industry. The company's adherence to international quality standards and regulatory approvals further enhances its competitive standing.

2Key Differentiators

Orbion Pharmaceuticals' key differentiators include its vertically integrated business model, covering the entire pharmaceutical value chain from research to distribution. The company's manufacturing facility is an Export Oriented Unit (EOU), predominantly exporting products to the US and EU markets, and is inspected and approved by various regulatory agencies, including the US FDA and the UK MHRA. Additionally, Orbion's extensive portfolio of approximately 29 ANDAs and 29 DMFs approved by the US FDA and European regulatory agencies underscores its capability to meet stringent regulatory standards.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Orbion Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Orbion Pharmaceuticals has demonstrated a strong track record in the pharmaceutical industry, with a focus on research, development, manufacturing, and marketing of generic pharmaceutical products. The company's manufacturing facility is an Export Oriented Unit (EOU), predominantly exporting products to the US and EU markets, and is inspected and approved by various regulatory agencies, including the US FDA and the UK MHRA.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Orbion Pharmaceuticals Private Limited

How many pharmaceutical products does Orbion Pharmaceuticals Private Limited export from India?

Orbion Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Terbinafine ($1.1M), Loperamide ($735.1K). Total export value is $1.9M.

What is Orbion Pharmaceuticals Private Limited's total pharmaceutical export value?

Orbion Pharmaceuticals Private Limited's total pharmaceutical export value is $1.9M, based on 66 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Orbion Pharmaceuticals Private Limited cover?

Orbion Pharmaceuticals Private Limited exports across 2 therapeutic categories. The largest are Antifungals (60.6%, 1 products), Gastrointestinal (39.4%, 1 products).

Get Full Orbion Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.